HLHui Liang

Hui Liang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hui Liang has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Congjie Xu

    Department of Urology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570311, China

    2 shared publications
  • Huolan Wei

    Department of Neurology Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Hainan Clinical Medical Center, Hainan Academician Team Innovation Center Haikou People's Republic of China

    2 shared publications
  • Jiyi Xu

    The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, 5 Ankang Lane, Dewai Avenue, Xicheng District, Beijing 100088 China; Advanced lnnovation Center for Human Brain Protection, Capital Medical University, 10 Xi tou tiao, You An Men Wai, Fengtai District, Beijing 100069 China

    2 shared publications
  • Shijun Hu

    Department of Neurology Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Hainan Clinical Medical Center, Hainan Academician Team Innovation Center Haikou People's Republic of China

    2 shared publications
  • Duowu Zou

    Department of Gastroenterology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China

    1 shared publication
  • Gang Wen

    Department of Emergency, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China

    1 shared publication

Latest Publications

  • Domain‐Specific Genotype–Phenotype Correlations in DNM1L Disorders: Insights Into Mutation Hotspots and Clinical Severity

    by Hui Liang, Zefu Chen, Shixiong Huang, Huolan Wei, Jiyi Xu, Shijun Hu

    DNM1L‐related disorders are rare mitochondrial diseases characterized by defective fission dynamics, often presenting with severe neurological manifestations. Current diagnostic and prognostic challenges stem from incomplete knowledge of domain‐specific genotype–phenotype correlations and limited clinical data. We report a novel GTPase effector domain (GED) variant (p.Val687del) and conduct a systematic analysis of 80 reported DNM1L cases with variants in the GTPase, Middle, or GED domains. Clinical, genetic, and survival data were extracted and analyzed to evaluate associations between mutation localization and clinical outcomes. Statistical comparisons of phenotypic severity, survival, and hotspot prevalence were performed. Functional validation of the novel variant was performed through in vitro overexpression, Western blot, immunofluorescence, and transmission electron microscopy. A novel GED deletion (p.Val687del) associated with peripheral neuropathy was identified, expanding the mutational spectrum. In vitro functional studies confirmed that this variant impairs DRP1 mitochondrial localization and induces severe ultrastructural damage, including fragmentation, swelling, and vacuolation. The preserved protein expression level excludes haploinsufficiency, consistent with a dominant‐negative mechanism. Within the total cohort of 81 patients (including our case), de novo variants were predominant (74.1%), with R403C representing a major mutational hotspot (28.4%). Middle domain mutations conferred the most severe prognosis, manifesting high frequencies of developmental delay (90.7%), epilepsy (83.7%), abnormal muscle tone (67.4%), abnormal EEG findings (74.4%), and cerebral atrophy (73.2%). In contrast, GTPase domain mutations primarily affected sensory pathways, with optic atrophy (57.6%) and peripheral neuropathy (27.3%) as hallmark features. Carriers of the R403C variant exhibited a 3.9‐year delay in disease onset compared to non‐carriers. This study establishes that mutation location in DNM1L dictates clinical severity, with Middle domain variants defining a severe encephalopathic subtype, while GTPase domain mutations predominantly target sensory pathways, leading to optic atrophy and peripheral neuropathy. These findings provide a framework for precision prognostication and targeted therapeutic strategies in DNM1L‐related disorders.

  • Genotype–Phenotype Correlation of ETF Dehydrogenase Gene‐Related Multiple Acyl‐ CoA Dehydrogenation Deficiency in Chinese Patients

    by Hui Liang, Ziling Ye, Lin Yang, Yue Liu, Minting Lin, Zhiqiang Wang, Xinyi Liu, Wan‐Jin Chen, Kang Yang

    Multiple Acyl‐CoA dehydrogenation deficiency (MADD) is an autosomal recessive inherited disease characterized by myopathic manifestation linked to fatty acid oxidation. The ETF dehydrogenase ( ETFDH ) gene is the most common gene associated with MADD. This study summarizes the clinical and genetic characteristics of 422 Chinese patients with ETFDH gene‐related MADD. We analyzed the clinical features, pathological characteristics, and genetic profiles of 30 ETFDH gene‐related MADD patients from our hospital and reviewed the clinical and mutational profiles of 392 previously reported Chinese patients. Patients were grouped based on mutation locations to analyze genotype–phenotype correlations. A total of 169 ETFDH mutations were identified, with missense mutation (70.4%) being the most common type. The most frequent mutations in the Chinese population were A84T, Y257C, and L409F, accounting for 19.9%, 10.5%, and 6% of total alleles, respectively. Patients carrying A84T had an earlier onset age by 10 years compared to other patients, while those with Y257C had a later onset age by 8 years. In the FAD‐binding domain group, females had a significantly earlier onset than males ( p < 0.05), while in the UQ‐binding domain/NULL group, males had an earlier onset than females ( p < 0.05). The A84T mutation is the most common ETFDH variant in China. Patients with A84T mutations experience earlier onset, while those with Y257C mutations have a later onset age. These findings highlight the importance of genotype–phenotype correlations in ETFDH ‐related MADD and emphasize the need for larger cohorts and functional studies to elucidate the impact of specific mutations.


  • Retracted
    Open Access

    Repetitive Transcranial Magnetic Stimulation Improves Neuropathy and Oxidative Stress Levels in Rats with Experimental Cerebral Infarction through the Nrf2 Signaling Pathway

    by Hui Liang, Congjie Xu, Shijun Hu, Gang Wen, Jie Lin, Tao Liu, Jiyi Xu

    Ischemic stroke poses a serious threat to human health. Its high morbidity, disability, and lethality rates have led to it being a research hotspot. Cerebral ischemia reperfusion injury is a difficult point in the treatment of ischemic stroke. In recent years, studies have shown that repeated transcranial magnetic stimulation (rTMS) can enhance cerebral ischemic tolerance and have a significant protective effect on reperfusion injury after ischemia, but its specific mechanism is unknown. The Nrf2/pathway plays a vital role in ischemia-reperfusion injury in the body environment. Therefore, in this experiment, the middle cerebral artery occlusion (MCAO) reperfusion model of SD rats was made to simulate the occurrence of experimental cerebral infarction by the suture method. After treatment with rTMS, it was studied whether it can regulate the expression of Nrf2 and HO-1, affect the content of MDA and SOD activity, and then activate the Nrf2 pathway to exert its brain protection. The results showed that after MCAO reperfusion, the neurological deficit score of rats increased, and the time to remove the bilateral stickers and the time to cross the balance beam increased, suggesting the successful establishment of the experimental cerebral infarction model. Detecting the brain tissue of experimental cerebral infarction rats found that the expression of Nrf2 and HO-1 decreased, the content of MDA increased, and the activity of SOD decreased. After rTMS treatment, the neuromotor function of experimental cerebral infarction rats improved, the expression of Nrf2 and HO-1 in the brain tissue gradually increased, the content of MDA decreased, and the activity of SOD increased. It indicates that the expression of Nrf2 and HO-1 in experimental cerebral infarction rats is reduced. After treatment with rTMS, it can improve the neuromotor function damage of the rats and reduce the level of oxidative stress. The mechanism may be through promoting the activation of the Nrf2 signaling pathway, acting on the expression of antioxidant proteins, such as HO-1 and SOD1, reducing oxidative stress damage, and playing a protective effect on brain tissue.


  • Open Access

    lncRNA small nucleolar RNA host gene 12 promotes renal cell carcinoma progression by modulating the miR‑200c‑5p/collagen type XI α1 chain pathway

    by Congjie Xu, Hui Liang, Jiaquan Zhou, Yang Wang, Shuan Liu, Xiaolin Wang, Liangju Su, Xinli Kang

    Renal cell carcinoma (RCC) is a primary malignant kidney cancer subtype. It has been suggested that long non‑coding RNAs (lncRNAs) serve important roles in the progression of kidney cancer. In fact, the lncRNA small nucleolar RNA host gene 12 (SNHG12) was discovered to be overexpressed in various types of cancer. However, to the best of our knowledge, the role of SNHG12 in RCC remains unclear. The present study aimed to investigate the function of SNHG12 and its underlying molecular mechanism of action in RCC. In patient samples and datasets from The Cancer Genome Atlas. Reverse transcription‑quantitative PCR, demonstrated that SNHG12 expression levels were upregulated in RCC tumor tissues, but not in normal kidney tissues. SNHG12 upregulation was also observed in RCC cell lines. Kaplan‑Meier survival analysis indicated a poor prognosis for those patients with RCC who had upregulated SNHG12 expression levels. Following lentivirus transduction, SNHG12 was successfully knocked down (validated by western blot analysis) and cell migration and invasion assays were performed. SNHG12 knockdown markedly inhibited cell viability and invasion, while increasing apoptosis in both A498 and 786O cell lines. The results of the luciferase reporter assay suggested that SNHG12 exerted its role by sponging microRNA (miR)‑200c‑5p, which led to the upregulation of its target gene, collagen type XI α1 chain (COL11A1). This was further validated, as miR‑200c‑5p inhibition reduced the effects of SNHG12 downregulation on cell viability and apoptosis, without affecting SNHG12 expression levels. Furthermore, the findings indicated that SNHG12 may partially exert its role through COL11A1, which was also upregulated in RCC. In conclusion, the results of the present study suggested that the SNHG12/miR‑200c‑5p/COL11A1 axis may be crucial for RCC progression, which provided an insight into potential therapeutic strategies for RCC treatment.


  • P2X3 receptor‐mediated visceral hyperalgesia and neuronal sensitization following exposure to PTSD‐like stress in the dorsal root ganglia of rats

    by Y-Q He, X-Q Lang, L Lin, L Ji, X-Y Yuan, Q Chen, Y-M Ran, H-S Chen, L Li, J-M Wang, et al.

    Background: Patients with posttraumatic stress disorder (PTSD) often share co‐morbidity with chronic pain conditions. Recent studies suggest a role of P2X3 receptors and ATP signaling in pain conditions. However, the underlying mechanisms of visceral hyperalgesia following exposure to PTSD‐like stress conditions remain unclarified.Methods: The behavior and hormones relevant for PTSD were studied. Visceromotor responses (VMR) and the abdominal withdrawal reflexes (AWR) to colorectal distention (CRD) were recorded to determine P2X3‐receptor–mediated alteration of hyperalgesia following single‐prolonged stress (SPS) exposure. Immunofluorescence, Western blotting, and patch‐clamp were used.Key Results: The escape latency, adrenocorticotropic hormone and cortisol were increased on days 7–14. Visceromotor responses and AWR was reduced at day 1 in SPS rats but increased to higher levels than in controls after exposure to day 7. Intrathecal administration of the P2X3‐receptor antagonist TNP‐ATP abolished the CRD response. Based on immunofluorescence and Western blotting analysis, SPS‐treated rats exhibited reduced P2X3 expression in dorsal root ganglia (DRG) after day 1 compared with controls. P2X3 expression in DRG was enhanced on day 7 after SPS and the increase of the P2X3 expression was maintained on day 14 and 21 compared with controls. The P2X3‐receptor agonist α,β‐me ATP (10 μM) induced a fast desensitizing inward current in DRG neurons of both control and SPS‐treated rats. The average peak current densities in SPS‐treated group were increased 3.6‐fold. TNP‐ATP (100 nM) markedly blocked all fast α,β‐me ATP‐induced inward currents in the DRG neurons both in control and SPS‐treated rats.Conclusions & Inferences: The data indicate an important role of P2X3 signaling in visceral hyperalgesia following PTSD‐like stress.